New eye drop JN002 aims to soothe dry eyes in early human test
NCT ID NCT07245017
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests a new eye drop called JN002 in 30 adults with dry eye disease. Participants will use the drops three times a day for 28 days. The goal is to see if the drops are safe and if they improve symptoms and eye surface health compared to a placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JN002 ophthalmic solution
- What this could lead to
- If it works, this could point toward a new eye drop to relieve dry eye symptoms and reduce eye surface damage.
- What could go wrong
- This is a very early, small trial with only 30 people. It is designed mainly to check safety, not prove effectiveness. The results may not lead to a treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRY EYE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Eye & ENT Hospital of Fudan University
RECRUITINGShanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can insulin eye drops quench dry eyes?
- Can a new eye drop soothe severe dry eye?
- New imaging tools put to the test for measuring dry eye treatment effects
- Could a special screen light reduce tired eyes and dryness?
- Nasal spray could make contact lenses more comfortable
- Dry eye drops may sharpen cataract surgery outcomes